Global Lutetium-177 Market Trends and Insights
Expanding Adoption of Targeted Radioligand Therapy
Targeted radioligand therapy is reaching more patients as approvals move beyond late-line treatment settings. In March 2025, the FDA expanded Pluvicto for patients with PSMA-positive metastatic castration-resistant prostate cancer who had not received taxane chemotherapy. In July 2026, the FDA approved Pluvicto with androgen receptor pathway inhibitor therapy for PSMA-positive metastatic hormone-sensitive prostate cancer. These decisions make the Lutetium-177 market less dependent on a narrow group of advanced-disease patients. They also increase demand for imaging, treatment scheduling, radiation safety processes, and staff who can administer repeated treatment cycles. The clinical use of radioligands therefore requires health systems to expand service capacity at the same pace as drug access.Regulatory Approvals and Label Expansion for Lu-177 Therapies
Regulatory approvals are shortening the period between clinical evidence and commercial adoption in major treatment regions. The FDA decisions in 2025 and 2026 gave Pluvicto access to earlier prostate cancer settings, supported by trial evidence reviewed through the agency’s oncology approval process. Japan’s PMDA approved Pluvicto for metastatic castration-resistant prostate cancer in September 2025, establishing a regulated pathway for use in a large Asia-Pacific health system. The European Commission granted centralized authorization for Ilumira, a no-carrier-added lutetium-177 chloride precursor, in March 2026. These actions expand the number of jurisdictions with established regulatory expectations for therapeutic Lu-177 material. They also make manufacturing quality, pharmacovigilance, and authorization maintenance central requirements for suppliers in the Lutetium-177 market.Limited High-Flux Reactor and Enriched Ytterbium-176 Availability
No-carrier-added Lu-177 production depends on enriched ytterbium-176 and access to suitable neutron irradiation capacity. ITM renewed its collaboration with the Institut Laue-Langevin in June 2025, securing priority access to half of the reactor’s available irradiation capacity for medical Lu-177 production. The agreement shows that supply security is based on long-term technical arrangements rather than spot purchasing. Kinectrics’ enrichment investment improves precursor availability, but enrichment alone does not replace reactor irradiation and authorized processing. The Lutetium-177 market consequently remains exposed to disruption at several points in the production chain. Producers that secure both precursor material and irradiation access may have a meaningful advantage when demand rises quickly.Other drivers and restraints analyzed in the detailed report include:
- Rising Cancer Burden and Demand for Precision Oncology
- Expansion of High-Purity Lu-177 Production Capacity
- Shortage of Licensed Theranostic Centers and Specialized Personnel
Segment Analysis
No-carrier-added material held 61.32% of revenue in 2026 and is projected to grow at a 17.54% CAGR through 2032. This portion of the Lutetium-177 market size reflects the need for high specific activity in therapeutic radiolabeling. No-carrier-added production uses enriched ytterbium-176 targets and is designed to reduce stable lutetium impurities. ITM describes no-carrier-added Lu-177 as a radioisotope supply option for therapeutic applications. The European Commission authorization for Ilumira covered no-carrier-added lutetium-177 chloride as a radiolabeling precursor. This regulatory decision supports the use of high-purity material within controlled pharmaceutical manufacturing systems.Carrier-added Lu-177 remains relevant for research work and some production pathways. Its use can be affected by lower specific activity because stable isotopes are present in the final material. This difference is important for products that need to deliver a therapeutic radionuclide while preserving target binding. The Lutetium-177 industry therefore places significant value on radionuclidic purity, batch consistency, and documented quality controls. Suppliers must validate material quality before it enters a radiopharmaceutical production process. Expanded production capacity does not remove the need for comparable standards across each source of high-purity material.
Complete Report Scope:
- By Product Type
- Carrier-Added Lutetium-177
- No-Carrier-Added Lutetium-177
- By Application
- Prostate Cancer Treatment
- Neuroendocrine Tumor Treatment
- Other Applications
- By End User
- Tertiary-Care Academic and Comprehensive Cancer Centers
- Hospitals
- Specialty Nuclear-Medicine Clinics
- Pharmaceutical and Biotechnology Companies
- Other End Users
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 43.21% of the Lutetium-177 market share in 2026. The region benefits from a large network of treatment sites, established oncology practices, and recent FDA label expansions for Pluvicto. Novartis reported more than 790 United States treatment sites for Pluvicto by late 2025. Canada is also strengthening the regional supply base through enriched ytterbium-176 capacity and planned reactor production. The regional opportunity is tempered by the need for qualified staff and dedicated treatment capacity. These operational needs will determine how fully new therapeutic approvals translate into administered patient doses.Asia-Pacific is projected to grow at a 16.54% CAGR through 2032. Japan’s PMDA authorized Pluvicto in September 2025, which gave providers a formal product and regulatory framework for metastatic castration-resistant prostate cancer treatment. Novartis also announced investment in a radioligand therapy manufacturing facility at its Sasayama site in Japan. Japan’s approval and local investment signal that therapy access and manufacturing are developing together. The region has a large potential patient base, but national authorization, reimbursement, imaging access, and trained-center availability will vary by country. Those differences mean that adoption is likely to proceed at different speeds across Asia-Pacific.
Europe has established radiopharmaceutical expertise but faces capacity constraints from workforce shortages. The Lutetium-177 market size in Europe is supported by authorized precursor products, including Ilumira, and by clinical capabilities in major treatment countries. The European workforce survey found vacancies across nuclear medicine departments, creating a barrier to wider treatment access. A German study found that coordination between urologists and nuclear medicine physicians can impede care pathways even in mature systems. In the Middle East, Africa, and South America, access is more closely tied to isotope availability, certified facilities, and specialist training. IAEA technical cooperation and local capacity building can help create the required technical base, but treatment delivery remains at an earlier stage than in North America or Europe. These mixed regions offer long-term growth potential rather than immediate broad-based commercial scale.
List of Companies Covered in this Report:
- Advanced Accelerator Applications S.A.
- Cardinal Health
- China National Nuclear Corporation
- Curium International Trading B.V.
- Eckert & Ziegler SE
- Eli Lilly and Company
- Evergreen Theragnostics, Inc.
- Institute for Radioelements
- ITM Isotope Technologies Munich SE
- NorthStar Medical Radioisotopes, LLC
- Novartis
- NRG PALLAS
- Nusano Inc.
- POINT Biopharma Global Inc.
- Radiopharm Theranostics Limited
- SCK CEN
- SHINE Technologies, LLC
- Telix Pharmaceuticals Limited
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Accelerator Applications S.A.
- Cardinal Health Inc.
- China National Nuclear Corporation
- Curium International Trading B.V.
- Eckert & Ziegler SE
- Eli Lilly and Company
- Evergreen Theragnostics, Inc.
- Institute for Radioelements
- ITM Isotope Technologies Munich SE
- NorthStar Medical Radioisotopes, LLC
- Novartis AG
- NRG PALLAS
- Nusano Inc.
- POINT Biopharma Global Inc.
- Radiopharm Theranostics Limited
- SCK CEN
- SHINE Technologies, LLC
- Telix Pharmaceuticals Limited

